ONCOLOGY / RESEARCH PAPER
Fabrication of Ag nanoparticles mediated by extract of plant and determination of the anti-human lung cancer effects
| 1 | Department of Thoracic Surgery，The Second Hospital of Hebei Medical University，Shijiazhuang 050000, Hebei, China, China |
| 2 | Administration Department of Nosocomial Infection, Hebei General Hospital, Shijiazhuang 050051, Hebei, China, China |
| 3 | Department of Cardiac Surgery，The Second Hospital of Hebei Medical University，Shijiazhuang 050000, Hebei, China, China |
| 4 | Department of Respiratory Medicine，The Second Hospital of Hebei Medical University，Shijiazhuang 050000, Hebei, China, China |
CORRESPONDING AUTHOR
Xiaodan Jiao
Department of Respiratory Medicine，The Second Hospital of Hebei Medical University，Shijiazhuang 050000, Hebei, China, China
Department of Respiratory Medicine，The Second Hospital of Hebei Medical University，Shijiazhuang 050000, Hebei, China, China
Submission date: 2021-08-30
Final revision date: 2021-11-13
Acceptance date: 2021-11-14
Online publication date: 2021-11-21
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The present work demonstrates the synthesis of Ag nanoparticles (Ag NPs) by aqueous extract of Thymus capitatus as green reductant and capping agent without any toxic reagent.
Material and methods:
Physicochemical characteristics of the said nanocomposite were elucidated by field emission scanning electron microscopy (FE-SEM), fourier-transform infrared spectroscopy (FTIR), and UV-Vis Spectroscopy.
Results:
The biogenic Ag NPs are uniformly globular. The Ag NPs has been explored biologically in the anticancer and antioxidant assays. In the cellular and molecular part of the recent study, the treated cells with Ag NPs were assessed by MTT assay for 48h about the cytotoxicity and anti-human lung adenocarcinoma properties on normal (HUVEC) and lung adenocarcinoma cell lines i.e. lung well-differentiated bronchogenic adenocarcinoma (HLC-1), lung moderately differentiated adenocarcinoma (LC-2/ad), and lung poorly differentiated adenocarcinoma (PC-14). The viability of malignant lung cell line reduced dose-dependently in the presence of Ag NPs. The IC50 of Ag NPs were 209, 185, and 106 µg/mL against HLC-1, LC-2/ad, and PC-14 cell lines, respectively. In the antioxidant test, the IC50 of Ag NPs and BHT against DPPH free radicals were 86 and 76 µg/mL, respectively.
Conclusions:
After clinical study, Ag NPs containing Thymus capitatus leaf aqueous extract may be used to formulate a new chemotherapeutic drug or supplement to treat the several types of human lung adenocarcinoma.
The present work demonstrates the synthesis of Ag nanoparticles (Ag NPs) by aqueous extract of Thymus capitatus as green reductant and capping agent without any toxic reagent.
Material and methods:
Physicochemical characteristics of the said nanocomposite were elucidated by field emission scanning electron microscopy (FE-SEM), fourier-transform infrared spectroscopy (FTIR), and UV-Vis Spectroscopy.
Results:
The biogenic Ag NPs are uniformly globular. The Ag NPs has been explored biologically in the anticancer and antioxidant assays. In the cellular and molecular part of the recent study, the treated cells with Ag NPs were assessed by MTT assay for 48h about the cytotoxicity and anti-human lung adenocarcinoma properties on normal (HUVEC) and lung adenocarcinoma cell lines i.e. lung well-differentiated bronchogenic adenocarcinoma (HLC-1), lung moderately differentiated adenocarcinoma (LC-2/ad), and lung poorly differentiated adenocarcinoma (PC-14). The viability of malignant lung cell line reduced dose-dependently in the presence of Ag NPs. The IC50 of Ag NPs were 209, 185, and 106 µg/mL against HLC-1, LC-2/ad, and PC-14 cell lines, respectively. In the antioxidant test, the IC50 of Ag NPs and BHT against DPPH free radicals were 86 and 76 µg/mL, respectively.
Conclusions:
After clinical study, Ag NPs containing Thymus capitatus leaf aqueous extract may be used to formulate a new chemotherapeutic drug or supplement to treat the several types of human lung adenocarcinoma.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.